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Abstract
Musashi1 (MSI1) is an RNA-binding protein that plays critical roles in nervous-system development and stem-cell self-
renewal. Here, we examined its role in the progression of glioma. Short hairpin RNA (shRNA)-based MSI1-knock down (KD) in
glioblastoma and medulloblastoma cells resulted in a significantly lower number of self renewing colony on day 30 (a 65%
reduction), compared with non-silencing shRNA-treated control cells, indicative of an inhibitory effect of MSI1-KD on tumor
cell growth and survival. Immunocytochemical staining of the MSI1-KD glioblastoma cells indicated that they ectopically
expressed metaphase markers. In addition, a 2.2-fold increase in the number of MSI1-KD cells in the G2/M phase was
observed. Thus, MSI1-KD caused the prolongation of mitosis and reduced the cell survival, although the expression of
activated Caspase-3 was unaltered. We further showed that MSI1-KD glioblastoma cells xenografted into the brains of NOD/
SCID mice formed tumors that were 96.6% smaller, as measured by a bioluminescence imaging system (BLI), than non-KD
cells, and the host survival was longer (49.366.1 days vs. 33.663.6 days; P,0.01). These findings and other cell biological
analyses suggested that the reduction of MSI1 in glioma cells prolonged the cell cycle by inducing the accumulation of
Cyclin B1. Furthermore, MSI1-KD reduced the activities of the Notch and PI3 kinase-Akt signaling pathways, through the up-
regulation of Numb and PTEN, respectively. Exposure of glioma cells to chemical inhibitors of these pathways reduced the
number of spheres and living cells, as did MSI1-KD. These results suggest that MSI1 increases the growth and/or survival of
certain types of glioma cells by promoting the activation of both Notch and PI3 kinase/Akt signaling.
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Introduction
In recent years, substantial research has elucidated the
involvement of cancer stem cells in brain tumors [1]. The concept
of cancer stem cells originated from observations that not all
cancer cells are equal [2]. Brain tumor tissue, for example, which
includes both rapidly proliferating cells and post-mitotic differen-
tiated cells, is hypothesized to be generated from the progeny of
cancer stem/progenitor cells. Although cancer stem cells are still
hypothetical, they are considered a new clinical target for cancer
treatments. Thus, many researchers have been trying to
distinguish and identify cell surface markers for cancer stem cells,
although the validity of these markers is still extensively debated.
In addition, cytoplasmic factors in proliferative cell fractions have
been investigated as selective markers of cancer stem cells. Among
these, the RNA-binding protein Musashi1 (MSI1) has been
identified as a candidate marker of cancer stem cells for
glioblastoma [3,4].
The Musashi (Msi) family of RNA-binding proteins is
evolutionarily conserved [5,6]. Msi was originally identified in
Drosophila melanogaster as a regulator of asymmetric cell division
[7,8], and its mouse counterpart is expressed in stem and
progenitor cells in various tissues [6]. Two members of this
family, MSI1 and Musashi2 (MSI2), have been identified in
mammals [5,9,10]. MSI1 is a marker of neural stem progenitor
cells (NS/PCs), and functions in stem-cell maintenance in the
nervous system and other tissues [11,12]. We previously
demonstrated that MSI1 activates the Notch signaling pathway
by translational repression of the mRNA for the Numb protein
[13], a negative regulator of the Notch-signaling pathway [14,15].
The mechanism of MSI1-mediated translational repression was
recently clarified in detail: MSI1 competitively inhibits the
interaction between eukaryotic translation initiation factor 4G
(eIF4G) and poly(A)-binding protein (PABP), thereby blocking
translation [16]. Through translational regulation, MSI1 supports
the maintenance of the renewal ability of NS/PCs [6]. In addition,
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translation of Numb in chronic myelogenous leukemia (CML) cells
[17]. MSI1 is expressed in NS/PCs in the developing embryonic
and mature adult brain [11,12]. In addition, many studies have
shown that MSI1 isup-regulated intumors suchasmedulloblastoma
[18,19], glioma [3,4], astrocytoma [20], retinoblastoma [21], and
colorectal adenoma [22]. Correlations have been established
between the expression level of MSI1 and the grade of malignancy,
the cells’ proliferative activity [4], and their immaturity, in human
glioma [3].
In the present study, to gain insight into the mechanism by
which MSI1 contributes to tumor-cell generation or maintenance,
we analyzed MSI1’s functions in malignant glioblastoma.
Furthermore, the contribution of MSI1 to cancer-cell progression
and its usefulness as a potential target for cancer therapy have not
been examined in animal models in vivo. A few reports have been
published on the role of MSI1-knockdown (KD) in suppressing
tumor-cell proliferation in a medulloblastoma cell line [23] and in
adenocarcinoma xenografts in nude mice [24]. However, there are
no studies clarifying the detailed role of MSI in the tumor growth
of glioblastoma, which is the most malignant form of glioma.
Hence, here we examined the role of MSI1 in the abnormal
growth of glioma cells. Our results show that MSI1 enhance the
growth and/or survival of glioma cells by inducing the Notch and
PI3K/Akt signaling pathways, through post-transcriptional regu-
latory mechanisms.
Results
MSI1 expression in glioblastoma cell lines and low-
passage cells obtained from glioblastoma specimens
We examined various glioma cells for MSI1 protein expression
by immunoblotting, and found it in human glioblastoma cell lines
(KNS42 and U251MG), low-passage glioblastoma cell lines
obtained from patients (GM1600, GM1605, and GM97), and a
human medulloblastoma cell line (Daoy) (Fig. 1A; compare with
the level in hNSCs). Each cell line and the primary cells from
glioblastoma patients expressed the MSI1 protein at different
levels, even though there were no differences in the patients’ poor
prognosis. The MSI1 protein expression was greater in cancer cells
than in hNSCs, except for the KNS42 glioblastoma line.
Lentivirus-mediated transduction of two separate anti-MSI1
shRNAs (MSI1-KD (i) and MSI1-KD (ii)) selectively depleted the
production of MSI1 protein in the U251MG line (Fig. 1B), to 43%
and 27%, respectively, and in the Daoy cells (Fig. 1C), to 36% and
21%, respectively, compared to the level in control cells
Figure 1. MSI1 expression in glioblastoma cell lines, medulloblastoma cell lines, and low-passage cells from glioblastoma patients.
(A) Immunoblots showing the MSI1 expression in human glioblastoma cell lines (U251MG, and KNS42), low-passage glioblastoma cells obtained from
patients GM97, GM1600, GM1605, and a human medulloblastoma cell line (Daoy). (B and C) The selective depletion of MSI1 protein by treatment with
shRNAs in U251MG cells (B) and Daoy cells (C). b-actin was used as a loading control in all the experiments.
doi:10.1371/journal.pone.0033431.g001
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sequences of MSI1 KD (i) and MSI1 KD (ii) are shown in
materials and methods.
Effect of MSI1-KD on glioma cell colony formation
To evaluate the effect of MSI1-KD on tumor cell colony
formation in vitro, we performed methylcellulose gel colony-
forming assays in the presence of EGF and FGF2. Under these
conditions, the cells form spherical colonies. The number of
colony (at a starting density of 2000 cells per well and counting
colonies larger than 100 mm), which indicated progenitor cell
proliferation, showed a reduction of 65%, 84%, and 58% in the
spheres generated from MSI1-KD U251MG, Daoy, and GM1605
cells, respectively. By contrast, in GM1600 (Fig. 2E,F) and KNS42
(Fig. 2.G,H) cells, which have lower endogenous MSI1 expression,
the number of colonies was not reduced by MSI1 shRNA
compared to control shRNA. Next, primary spheres were
dissociated into single cells and further cultured in methylcellu-
lose-containing medium, resulting in the reformation of spheres
(secondary spheres). These secondary spheres were used in all
experiments. MSI1-KD reduced the number of spheres compared
to control shRNA in U251MG (Fig. 2A) and Daoy cells (Fig. 2C).
The spheres were then dissociated and the total cell number was
counted. On day 15, the total cell number in MSI1-KD spheres
was reduced by 83%, 55% and 39% of control in U251MG
(Fig. 2I), Daoy (Fig. 2J) and GM1605 (Fig. S3) cells, respectively;
however no decrease in cell number was observed in GM1600
(Fig. 2K) and KNS42 (Fig. 2L) cells, suggesting that MSI1 does not
contribute to proliferation in these cells. Sphere number and cell
survival were decreased in U251MG cells exposed to DAPT (c-
secretase inhibitor) and in Daoy cells exposed to LY294002 (PI3
kinase inhibitor) and DAPT. These results suggest that MSI1
regulates both the Notch pathway and the PI3 kinase/Akt pathway
in glioma cells. This is consistent with the observation that cell
proliferation was repressed in MSI1-KD spheres compared to
control spheres, and suggests that MSI1-KD may disorder the cell
cycle in U251MG and Daoy.
MSI1-KD inhibits the growth of glioblastoma xenografts
To assess the effect of MSI1-KD on tumor growth, U251MG or
Daoy cells, treated with MSI1-KD (ii) or control shRNA, were
transplanted into the right striatum of NOD-SCID mice. The
transplanted cells were transfected with a bicistronic reporter gene
encoding a luminescent protein (CBRluc) and a fluorescent protein
(Venus) separated by an IRES. The tumor growth was monitored
in live animals by bioluminescence imaging (BLI) using the IVIS
systemH (Caliper Life Sciences, Hopkinton, MA), with which the
grafted cells could be identified by their fluorescent Venus and
bioluminescent Luciferase signals. The results of the experiments
using U251MG and Daoy cells are shown in Fig. 2, respectively.
Treatment of U251MG cells with MSI1-KD resulted in a 96.6%
reduction in BLI on Day 28 compared to the control shRNA
group (Fig. 2A and B), and the host survival time in the MSI1-KD
group (49.366.1 days) was significantly longer than that in the
shRNA control group (33.663.6 days; P,0.01) (Fig. 2C). In Daoy
cells, MSI1-KD cells resulted in a 97.3% reduction in BLI on Day
28 compared to the control shRNA group, the survival time of the
MSI1-KD group (45.565.4 days) was significantly longer than that
of the shRNA control group (34.064.1 days; P,0.01)(Fig. 2D and
E). The successful transplantation of the control U251MG cells
(Fig. 2F-a) and of MSI1-KD U251MG cells (Fig. 2F-b) into the
mouse brain was confirmed by hematoxylin and eosin staining.
However, unexpectedly, the number of positive cells for
phosphohistone H3 (Fig. 2G-b, d) in the MSI1-KD-cell-trans-
planted mice was much larger than the number in the controls
(Fig. 2G-a, c), indicating that the peri-metaphase (M-phase) cell-
cycle regulation might be abnormal in the MSI1-KD cells. Taken
together, these results suggest that the downregulation of MSI1 in
the tumors led to a reduction in tumor tissue mass and to
disordered cell proliferation and cell-cycle regulation.
Treatment with MSI1-KD induces mitosis and G2/M arrest
in spheres of glioblastoma cells
The decrease in the MSI1 protein level in brain tumor cells led
to a reduction in the transplanted tumor mass in the host mouse
brain (Fig. 2) and a repression of cell proliferation (Fig. 3). We
therefore surmised that MSI1 regulates both the cell-cycle and cell
survival. To analyze the effects of MSI1-KD on the cell cycle,
MSI1-KD U251MG cells were analyzed for cell-cycle distribution
by flow-cytometry. Compared to control cells, a higher number of
MSI1-KD U251MG cells accumulated in the G2/M phase, and
significantly fewer cells in the G0–G1 and S1 phases were
detected. These results clearly demonstrate that the knockdown of
MSI1 in U251MG cells resulted in changes in the cell-cycle phase
distribution (Fig. 4A).
To further analyze the cell-cycle status of MSI1-KD U251MG
cells, we used a ubiquitination-based fluorescent cell-cycle
indicator (Fucci) probe-based system, in which transfected cells
show green fluorescence during the G2/M phase of the cell cycle
[25]. The MSI1-KD cells retained the green fluorescence for a
much longer time (4 days), as observed by time-lapse microscopy
(Fig. 4B), than the control U251MG cells, suggesting a clear
relationship between MSI1 and the cell cycle.
The cell colonies were then dissociated, fixed, and immuno-
stained for phosphohistone H3 (PH3) to assess the cells’ mitotic
status. Both MSI1-KD U251MG cells and control U251MG cells
stained positive for PH3, a marker for mitosis. Compared to the
control cells, however, the MSI1-KD-transduced U251MG cells
(Fig. 4C and 4D) showed a significant, 10-fold increase in PH3-
positive cells. In GM1605 cells, the MSI1-KD-transduced cells
demonstrated an increase of 2.8-fold (Fig. S1). Taken together,
these results indicate that MSI1 is involved in cell-cycle control,
especially at the M-phase, in brain tumor cells.
MSI1-KD increases Caspase-3-independent cell death
through a mechanism other than cellular senescence or
apoptosis
Apoptosis, senescence, or the alteration of cell survival was
possible reason for the cell-number reduction in the MSI1-KD
tumor cell colonies. To determine whether any of these processes
was involved, we performed immunocytochemical experiments.
To evaluate the state of senescence, the MSI1-KD cells were
stained for senescence-activated b-Galactosidase (SA-b-Gal) [26].
There was no significant difference between the control and MSI1-
KD groups on day 30 (Fig. 5A and B). Next, the MSI1-KD cells
were dissociated, fixed, and immunostained for TUNEL and anti-
activated Caspase-3 to examine apoptotic targets. There was no
significant difference in the number of TUNEL- (Fig. 5C and 5D)
or activated Caspase-3-positive cells (Fig. 5E and 5F) between the
MSI1-KD U251MG cells and control cells. Similar results were
obtained using MSI-KD GM1605 cells (Fig. S2). Further flow-
cytometric population analysis showed that the number of annexin
V positive cells in the MSI1-KD group were the same cells
compared with control group (Fig. 5I), inducing the conclusion
that there were no difference in apoptotic cells between MSI1-KD
U251MG cells and control cells. However, flow-cytometric
population analysis revealed that the number of cells that
Musashi1-Mediated Modulation of Glioma Growth
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cells compared with control cells (Fig. 5G and 5H), indicating that
there were more dead MSI1-KD U251MG cells than control cells.
Therefore, MSI1-KD appeared to induce cell death simultaneous-
ly with the occurrence of cell-cycle dysregulation. However, no
increase in cleaved-Caspase-3-positive cells and in TUNEL
positive cells were observed in the MSI1-KD tumor cells.
Collectively, these results suggested that the MSI1-KD-induced
reduction in colony-forming cells in the glioblastoma cell line
occurs through cell death, but via a pathway other than apoptosis,
possibly necrosis.
MSI1-KD alters the expression of sev e r a lc e l lc y c l e - r e l a t e d
markers and PTEN-PI3 kinase/Akt pathway-related molecules
in some glioma cells
To clarify the events occurring in the MSI1-KD cells, we
analyzed whether there were differences in the expression levels of
various proteins between MSI1-KD cells and control shRNA-
transduced U251MG (Fig. 6A) and Daoy cells (Fig. 6C). MSI1
activates Notch signaling thorough the MSI1-Numb-Notch
pathway [6,27], and the excessive translational repression of
Numb by the constitutive overexpression of MSI promotes the
development and progression of CML blast crisis [17]. Therefore,
we examined the MSI1-KD mediated alteration of the Numb
protein level and Notch activity, as represented by the cleaved-
Notch level in glioma cells. Furthermore, because we found that
MSI1 reduction was accompanied by cell-cycle prolongation, as
shown in Figs. 3 and 4, and apparently regulated the cell-cycle,
especially at the M-phase, we examined the changes in cell-cycle-
related markers caused by MSI1-KD. Cyclin B1 is involved in
mitosis, and Cyclin D1 is involved in the G1/S transition; PTEN
are suppressors of Akt pathways. An increased expression of the
p16 gene as organisms age reduces the proliferation of stem cells
[28]. Since our results shows MSI1 was involved in glioma
survival, we surmised MSI1 was related to the regulation of
PTEN-PI3 kinase/Akt pathway. Our results showed that MSI1-
KD induced the up-regulation of Numb, Cyclin B1, p16, and
reduced the level of cleaved Notch in U251MG cells. Furgth-
ermore, MSI1-KD up-regulated PTEN, and down-regulated the
level of cleaved Notch and Akt phosphorylation at theonine 308
(Phospho-Akt (Thr308)) in PTEN-intact Daoy cells (Fig. 6C).
There was no change in the expression of Cyclin D1 compared to
control U251MG cells (Fig. 6A) and no change in the expression of
Akt in Daoy cells (Fig. 6C). Cyclin B1 was more strongly expressed
in MSI1-KD cells than in control cells by immunocytochemistry
(Fig. 6B). In the MSI1 KD cells, Cyclin B1 was located in the
cytoplasm, indicating the cells were in early mitosis. In M-phase,
the nucleus has split in two and is not entirely stained by Cyclin B1
(Fig. 6B). Taken together, these results show that a decrease in
MSI1 led to decreases in both the Notch pathway in U251MG
cells and the PI3 kinase-Akt signaling activity in Daoy cells.
Furthermore, Cyclin B1 was up-regulated, which is consistent with
the prolongation of metaphase observed upon MSI1-KD.
Discussion
Here, by knocking down MSI1 in glioma cells, we found that
MSI1 may promote cell proliferation and survival, and its loss can
be detrimental. MSI1-KD in medulloblastoma Daoy cells induces
apoptosis and mitotic catastrophe, suggesting a potential mecha-
nism for its role in tumorigenesis [23]. MSI1-KD in adenocarci-
noma cells results in tumor growth arrest in xenografts, reduced
cancer cell proliferation, and increased apoptosis [24]. MSI1 acts
as a key determinant of the mammary lineage through its inability
to coordinate cell-cycle entry and activate the Notch and Wnt
pathways [24,27]. In human breast cancer patients, MSI1 is a
negative prognostic indicator of patient survival, and is indicative
of tumor cells with stem cell-like characteristics [29]. These
previous reports and our current findings showed that MSI1-KD
reduces tumor-cell survival and tumor-xenograft growth, and
support its possible identification as a novel target for glioblastoma
therapy.
In this study, using an in vitro approach, we showed that MSI1 is
highly expressed in various glioblastoma cell lines (Fig. 1). MSI1-
KD treated cells generated a reduced number of glioma spheres
(Fig. 2) and stained positive for M-phase markers (Fig. 4). In
addition, a tumor-growth assay in vivo using NOD-SCID mice
demonstrated that xenografts expressing MSI1-KD resulted in a
smaller tumor size (as seen by a marked decrease in BLI) and
longer mouse survival compared with their counterparts treated
with control shRNA-expressing xenografts (Fig. 3). These results
were consistent with previous studies indicating that high MSI1
expression is associated with a poor prognosis in glioma [3,4].
Furthermore, inglioblastomacells,we found that MSI1-KD led to
decreased Notch signaling activity, as represented by the level of
cleaved Notch, and to the accumulation of Numb. Our group
previously reported that MSI1 represses Numb translation and
consequently augments the Notch signaling activity [27]. Other
groups have shown that MSI1 up-regulates the Notch signaling
activity in medulloblastoma [18], colon cancer [24], mammary
progenitor cells [29], and endometrial carcinoma [30]. The nuclear
translocation of Notch1, which results in the activation of its
downstream pathway, may contribute to the induction of tumori-
genesis by increasing proliferation and inhibiting apoptosis [2,31].
A recent report showed that the MSI2-mediated downregula-
tion of Numb significantly impairs the development and
propagation of CML blast crisis in vitro and in vivo [17]. Indeed,
disorganization of the Notch signaling balance by breakdown of
the Musashi-Numb axis is directly linked to the malignancy in the
Figure 2. Colony-forming cell assay and effects of MSI1-KD. (A,B,C and D) MSI1 shRNA decreased the number of colony-forming cells. (A)
Representative images of the secondary colonies formed by the control shRNA-treated and MSI1-KD U251MG cells. (Bar=500 mm). The number of
spheres was reduced in U251 cells exposed to 10 mM DAPT. (B) On Day 30, secondary spheres larger than 100 mm in diameter were counted. U251MG
glioblastoma cells transduced with MSI1 shRNA and cells treated with 10 mM DAPT (c-secretase inhibitor) generated significantly fewer spheroid cell
colonies than cells transduced with control shRNA. Error bars represent SEM, *P,0.01(C) Representative images of the secondary colonies obtained in
cells transduced with control shRNA and in MSI1-KD PTEN-intact Daoy cells exposed to 10 mM LY294002 (PI3 kinase inhibitor) and DAPT. (D) On Day
30, secondary spheres larger than 100 mm in diameter were counted. PTEN-intact Daoy cells transduced with MSI1 shRNA and cells exposed to
LY294002 and DAPT generated significantly fewer spheroid colonies than cells transduced with control shRNA. Error bars represent SEM, *P,0.01(E
and G). Representative images of the secondary colonies formed by cells expressing low endogenous MSI1. GM1600 (Fig. 2E) and KNS42 (Fig. 2G)
transduced with control shRNA and MSI1 shRNA (F and H). On day 30, secondary spheres larger than 100 mm in diameter were counted. There was no
significant difference between control shRNA and MSI1 shRNA in GM1600 (Fig. 2F) or KNS42 (Fig. 2H). (I, J, and K) MSI1-KD inhibits colony formation.
Proliferation was assessed in glioblastoma and medulloblastoma cell lines (cell density of 2610
3 cells/well) were assessed for cell proliferation by cell
counting. The total cell count in the MSI1-KD groups on day 15 was reduced by 83%, and 55% in the (I) U251MG and (J) Daoy cells, respectively, as
compared to the control groups.
doi:10.1371/journal.pone.0033431.g002
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4 human glioblastoma cells were
transplanted into the right striatum of NOD/SCID mice (n=4), and tumor growth was monitored in live animals. The MSI1-KD group exhibited better
survival than the control group (n=4,
*P,0.05). (A) Representative BLI images of mice receiving implants of MSI1 shRNA lentivirus-transfected
U251MG cells on day 28. (B&D) Relative photon count of BLI compared with that day0 was shown. The tumor average photon count in MSI1-KD
group was inferior to that in control groups in U251MG cells (Fig. 3B) and in Daoy cells (Fig. 3D) (C) Kaplan-Meier survival curves for the control and
MSI1-KD mice in U251MG cells (
*P,0.05). The survival time in the MSI1-KD group (49.366.1 days) was significantly longer than that in the shRNA
control group in U251-MG cells (33.663.6 days; P,0.01). (E) Kaplan-Meier survival curves for the control and MSI1-KD mice are shown in Daoy cells
(
*P,0.05). The survival time of the MSI1-KD group (45.565.4 days) was significantly longer than that of the shRNA control group in Daoy cells
(34.064.1 days; P,0.01). (F) Mouse brain transplanted with control cells (F-a) and MSI1-KD cells (F-b) was stained for hematoxylin and eosin
(Bar=1 mm). (G) Brain transplanted with control cells [G-(a, c)] and MSI1-KD cells [G-(b, d)] was immunostained for PH3 [(a, b) Bar=800 mm (c, d)
Bar=200 mm]. In G-(a, b), surrounding arrows show the transplanted tumor area. G-(c, d) indicated the high magnification images of the squared
region of G-(a, b), respectively.
doi:10.1371/journal.pone.0033431.g003
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PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33431Figure 4. Knockdown of MSI1 induces G2/M arrest. MSI1-KD cells were analyzed by fluorescence-activated cell sorting. A representative cell-
cycle profile for each treatment is indicated. 2N represents the G0–G1 phase and 4N represents the G2/M phase. An increased number of MSI1 KD-
positive cells accumulated in the G2/M phase. (B) Time-lapse microscopy using a fluorescent ubiquitination-based cell-cycle indicator (Fucci) probe
system showed that MSI1-KD cells retained the green fluorescence for a much longer time (4 days). Error bars represent SEM, *P,0.01.The spheres
were dissociated, and the dissociated cells were fixed to coverslips and stained for PH3 in U251MG cells (C and D). Cell counts are plotted as bar
graphs. An average of 25 high-power fields was counted. Error bars represent SEM, *P,0.01. (D) Representative images of control cells and MSI1-KD
cells stained for PH3 and Hoechst. There were more PH3-positive MSI1-KD cells than control cells. (Bar=500 mm).
doi:10.1371/journal.pone.0033431.g004
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PLoS ONE | www.plosone.org 8 March 2012 | Volume 7 | Issue 3 | e33431Figure 5. MSI1-KD cells may undergo non-apoptotic cell death. (A and B) SA-b-Gal staining was performed to assess the senescence in
controls and MSI1-KD cells. (A) Representative images of control cells and MSI1-KD cells stained for SA-b-Gal (Bar=200 mm). (C, D, E, and F) Colonies
were dissociated, and the cells were fixed to coverslips and stained for TUNEL in U251 MG cells (C and D), and for cleaved Caspase-3 in U251MG cells
(E and F). Cell counts are plotted as bar graphs. An average of 25 high power fields was counted. (G and H) The number of PI-positive cells (indicating
dead cells) was greater in the MSI1-KD cell population than in the control cell population. Error bars represent SEM. *P,0.01.**P,0.01. (I) The number
of annexinV-positive in the MSI1-KD cells (indicating apoptotic cells) was not different from that in the control cell population.
doi:10.1371/journal.pone.0033431.g005
Figure 6. MSI1-KD changed the expression level of various genes. (A) Immunoblots showing the expression of various cell-cycle markers and
downstream genes of MSI1 in control and MSI1-KD in U251MG cell lines. MSI1-KD resulted in the up-regulation of Numb, Cyclin B1, and P16, the
downregulation of cleaved Notch, and no change in CyclinD1. (B) Immunocytochemistry showed that Cyclin B1 was potently expressed in MSI1-KD
cells compared with control cells. (Bar=200 mm). (C) In PTEN-intact Daoy cells, the immunoblot analysis showed that MSI1-KD led to the up-
regulation of PTEN, and down-regulation of cleaved Notch and p-Akt with no change in total Akt level. Error bars represent SEM (*P,0.01).
doi:10.1371/journal.pone.0033431.g006
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PLoS ONE | www.plosone.org 9 March 2012 | Volume 7 | Issue 3 | e33431CML blast crisis [32]. Consequently, modulation of the Musashi-
Numb-Notch pathway influences the tumorigenicity of various
tumors including glioblastoma, as described in this study. MSI1-
KD probably leads the glioblastoma cells to mitotic catastrophe,
resulting in cell death by the accumulation of Numb protein and
subsequent inhibition of the Notch signaling pathway. (Fig. 7)
The reduction of MSI1 in glioblastoma cells caused other
abnormalities in cell-cycle regulation. MSI1-KD increased the
number of PH3-positive cells (Fig. 4C, Fig. S1), and the cell-cycle
analysis using PI revealed that the number of MSI1-KD cells in the
G2/M phase increased (Fig. 4A). Time-lapse assays using Fucci
demonstrated that MSI1-KD sphere cells stayed longer in the S/
G2/M phase of the cell cycle than cells in control spheres (Fig. 4B).
There was a significant decrease in the number of MSI1-KD cells
accumulating in the G0–G1 phase, supporting the previous
finding that MSI1 promotes G1/S transition through the
activation of both the Notch and Wnt signaling pathways [29].
Immunoblot analysis revealed that MSI1-KD in glioblastoma cells
resulted in the accumulation of Cyclin B1 due to prolongation of
the M-phase (Fig. 6). Interestingly, MacNicol’s group found that
Msi1 activates the cytoplasmic polyadenylation of c-Mos, Cyclin B1,
and Cyclin B4 mRNA in Xenopus oocytes [33,34]. In the Xenopus
oocyte, cytoplasmic polyadenylation is thought to be linked with
translation activation [35]. The c-Mos gene is related to meiotic
cell-cycle progression. However, in our glioblastoma cells, Cyclin
B1 was probably appropriately down-regulated by MSI1 through
an indirect or direct pathway. Why MSI1 has different functions in
various contexts is an interesting question for future study.
There was no difference in the expression of the apoptotic
marker activated Caspase-3 (Fig. 5E, 5F, and Fig. S2) or in
TUNEL staining (Fig. 5C and 5D) in MSI1-KD-expressing cells,
and the number of annexinV-positive cells was the same as the
shRNA-transduced control cells (Fig. 5I), but the number of PI-
positive dead cells increased (Fig. 5G and 5H). In the present
study, the decrease in MSI1 in glioblastoma cells led to cell growth
retardation and a defect in non-apoptotic cell survival, accompa-
nied by a cell-cycle abnormality, which resulted in an ectopic
accumulation of Cyclin B1. These findings showed that the
decrease in cell growth was caused by prolongation of the cell
cycle, especially by a prolonged M-phase, and an increase in cell
death by a Caspase-3-independent mechanism. Previously,
inappropriate increases in nuclear Cyclin B1 have been found in
mitotic catastrophe in colorectal adenocarcinomas, nasopharyn-
geal carcinoma, and colon cancer [36,37]. It has been suggested
that an elevated level of Cyclin B1 or premature activation and
nuclear entry of CDK1/Cyclin B1 may be sufficient to induce
mitosis before the completion of DNA replication, thus causing cell
death during mitosis [38]. An inhibition of Notch signaling results
in prolonged G2-M cell-cycle arrest before the induction of
apoptosis in Kaposi’s sarcoma, and leads to mitotic catastrophe, in
which the destruction of nuclear structures is observed [39].
These phenomena correspond to mitotic catastrophe. The
initial step in mitotic catastrophe is evidence of DNA damage in a
cell that is undergoing mitosis [39]. A hallmark of mitotic
catastrophe is the entry of cells into mitosis despite the presence
of damaged DNA, resulting in the activation of cell death [40,41].
These facts led us to hypothesize that Notch inhibition in
glioblastoma cells results in mitotic catastrophe, which is finally
resolved in prolongation of the cell cycle and delayed cell growth.
Therefore, MSI1-KD probably leads the glioblastoma cells to
undergo mitotic catastrophe, resulting in cell death caused by the
accumulations of Numb and Cyclin B1 proteins and by the
inhibition of Notch.
It is known that glioblastomas often contain mutations and
deletions in the tumor suppressor gene PTEN, whose alteration
affects the phosphatidyl-inositol-3 kinase (PI3K)/Akt pathway
[42,43]. In MSI1-KD Daoy cells, the expression of PTEN was
increased (Fig. 6C). Recently, in an MSI1-RNA co-immunopre-
cipitation experiment, we found that PTEN mRNA is a putative
downstream target of MSI1 in mouse neural stem cells (Imai et al.,
unpublished results). In the present study we observed an increase in
the PTEN protein level, a decrease in the phosphorylation level of
Akt (at Thr308), and no alteration in the Akt protein level in
MSI1-KD cells. Accordingly, it is possible that PTEN is down-
regulated by MSI1 in glioma cells. The number of spheres and
living cells was reduced in PTEN-intact Daoy cells upon exposure
to LY294002 (PI3 kinase inhibitor) and DAPT (c-secretase
inhibitor), a phenotype also observed upon MSI1-KD (Fig. 2).
We hypothesize that competence for cell survival may be
regulated by the MSI1-PTEN-PI3 kinase/Akt pathway in glioma
cells. PTEN negatively regulates neural stem cell self-renewal by
modulating G0–G1 cell-cycle entry [44]. Notably, in hematopoi-
etic stem cells, deletion of the Pten gene results in the generation of
leukemic stem cells but the depletion of normal hematopoietic
stem cells [45]. Taking these reports and our data together, our
current model is that MSI1 plays a role in glioma development by
enhancing the self-renewal and survival of glioma cells through the
MSI1-Numb-Notch pathway and the MSI1-PTEN-PI3 kinase-Akt
pathway (Fig. 7).
Although the MSI1-binding targets in HEK293 have been
described [46], they are not known in glioblastoma cells, and our
future research will be directed at identifying the downstream
pathway of MSI1 through microarray analysis and proteomic
profiling in glioblastoma cells. Knowledge about the downstream
target genes of MSI1 will shed light on the mechanism by which
these proteins promote cancer cell progression. Based on our in
vitro and in vivo findings, we propose that tumor stem cells treated
with MSI1-KD lose their self-renewal ability and undergo a non-
apoptotic programmed cell death, which may explain the
difference in tumor growth between the control and MSI1-KD
groups. However, results showed that the level of MSI1 expression
did not always correlate with malignancy: considering the fact that
Figure 7. Current model for the involvement of Musashi-1 in
glioma development. The elevated level of the RNA-binding protein
Musashi-1 leads to the down-regulation of Numb and PTEN (Imai et al.,
unpublished), resulting in increased activity of the Notch and PI3K/Akt-
pathways, respectively. These events could lead to the enhanced self-
renewal and survival of glioma cells and subsequent glioma develop-
ment. In addition to these mechanisms, the downregulation of Cyclin
B1 expression and prolongation of the cell cycle could be involved in
Musashi1-mediated glioma development.
doi:10.1371/journal.pone.0033431.g007
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cellular origin, it is conceivable that both MSI1-dependent and -
independent mechanisms are involved in the regulation of
malignancy in glioma.
Materials and Methods
This study was approved by our local institutional ethical review
board,‘‘KEIO university ethical committee’’. The establishment of
glioblastoma cell lines GM97, GM1600, and GM1605 was
specifically approved by the institutional review board of the
university of California at Los Angels. This study was performed in
accordance with the ethical standards laid down in the 1964
Declaration of Helsinki. All the animal experiments were conducted
according to the Guidelines for the Care and Use of Laboratory
Animals of the Keio University School of Medicine. The KEIO
permit number is #2634 and the UCLA approval number is:
UCLA IRB APPROVED PROTOCOL: #10-000344. Written
informed consent was obtained from all participants involved in the
study.
Cell culture
Human glioblastoma cell lines U251MG, KNS42, KNS81,
KNS60, and SF126 were purchased from Japanese Collection of
Research Bioresources (JCRB). Other glioma cell lines, U87MG
and T98G were purchased from ATCC. GM97, GM1600, and
GM1605 were established from surgically resected specimens from
glioblastoma patients at the University of California Los Angeles,
in accordance with protocols approved by the University of
California Los Angeles Institutional Review Board, as previously
described [29,47]. Briefly, after the tumor was histologically
diagnosed as glioblastoma by a board-certified neuropathologist, it
was finely minced with a scalpel and resuspended in complete
Iscove’s modified 20% Dulbecco’s medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) (Omega), 2 mM
glutamine, 5 mg/mL each of insulin and transferrin, 5 ng/mL
selenium (ITS Culture Supplement; Collaborative Biosciences,
Bedford, MA). The GM97, GM1605, and GM1600 cell lines were
passaged fewer than 10 times. The T98G, KNS42, KNS81,
KNS60, SF126, GM97, GM1605, and GM1600 cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
(Sigma-Aldrich Chemical Co., St. Louis, MO). The U251MG cell
line was maintained in modified Eagle’s medium (MEM) (Sigma-
Aldrich). Sphere formation was performed as previously described
[48]. Cells were cultured in serum-free DMEM HAM/F12
medium (Sigma-Aldrich Chemical Co., St. Louis, MO) supple-
mented with 16B27 (Invitrogen), 20 ng/mL epidermal growth
factor (EGF; Peprotech Invitrogen), and 20 ng/mL fibroblast
growth factor-2 (FGF-2; Peprotech Invitrogen) for immunostain-
ing and western blot experiments. The cultures were incubated at
37uC in a 5% CO2 cell culture incubator (Sanyo). Glioblastoma
and medulloblastoma cells grown as sphere cultures were collected
by gentle centrifugation (8006g, 5 min) and trypsinized with
0.05% TrypLESelect (Invitrogen Corp., Carlsbad, CA) for 5 min
by pipetting. Cells were washed twice with phosphate buffered
saline (PBS), counted, and seeded at a density of 2000 cells per
200 mL into 96-well ultralow-attachment plates (Corning).
Immunoblotting
Immunoblot analysis was performed as described previously
[16]. Total cell extract (about 30 mg) was fractionated by 10%
SDS-PAGE. Proteins were detected using the appropriate primary
antibodies and horseradish peroxidase-linked secondary antibod-
ies, and visualized by chemiluminescence (Amersham Biosciences).
Antibodies used in immunoblot analysis
The following primary antibodies were used for immunoblots:
rat anti-MSI1 14H1 [49] or anti-MSI1 14H1 biotinylated (1:500),
rabbit anti-PTEN (1:500) (Cell Signaling Technology), rabbit anti-
p16 (1:500) (Cell Signaling Technology), mouse anti-p21 (1:500)
(Cell Signaling Technology), rabbit anti phosphorylation at
Threonine 308 of Akt (1:250) (Cell Signaling Technology), rabbit
Akt (1:500) (Cell Signaling Technology), and mouse anti-b-Actin
(1:1000) (Sigma-Aldrich Corp MO). For detection, horseradish
peroxidase (HRP)-conjugated anti-rabbit IgG (Jackson ImmunoR-
esearch) (1:1000), HRP-conjugated anti-rat IgG (Jackson Immu-
noResearch) (1:1000), HRP-conjugated anti-mouse IgG (Jackson
ImmunoResearch) (1:1000), and HRP-conjugated anti-goat IgG
(Jackson ImmunoResearch) (1:1000) were used.
Colony-forming assay
Primary spheres were collected, incubated in 0.25% trypsin-
EDTA for 5 min at 37uC, and triturated until single-cell suspension
was obtained. The cells were spun at 800 g for 5 min at 4uCa n d
resuspended in the aforementioned sphere culture medium. The
cells were cultured in the above medium with 0.8% methylcellulose
(Nacalai Tesque 22224-55) as previously described [50]. The
colony-forming cell assay was performed by seeding 3610
3 tumor
cells/well into 96-well ultralow-attachment plates (Corning) in
200 mL medium. Every four days, 50 mL of the fresh growth
medium was added. The number of colonies was counted after 30
days, once the spheres were greater than 100 mm in diameter. The
colony (sphere) was observed using fluorescence microscopy
(BIOREVO BZ-9000; Keyence). U251MG and DAOY cells were
exposed to 10 mM LY294002 (PI3 kinase inhibitor, Promeg,WI)and
10 mMD A P T( c-secretase inhibitor, Sigma-Aldrich Corp., Saint
Louis, MO) for 16 days. The culture medium was replaced every 4
days. Sphere formation and cell numbers were assessed. The
proteins were collected 24 hours after the last addition of LY294002
and DAPT. For immunocytochemistry, the spheres were collected,
incubatedin0.25%trypsin-EDTA for5 minat37uC,and triturated
until a single-cell suspension was plated in the aforementioned
sphere culture medium without serum on poly-D-lysine/laminin
(Sigma P7405/Invitrogen 23017-015)-coated 24-well chamber
slides (Iwaki 5732-008) and cultured for 2 hours. The samples were
observed with a universal fluorescence microscope (Axioplan 2
imaging; Carl Zeiss).
Flow cytometer-assisted cell sorting
For cell-cycle analysis, dissociated cells (1610
6 cells) were
incubated in 1 ml of hypotonic propidium iodide (PI) solution
(1 mg/ml PI, 0.1% citric acid, 0.2% NP-40, 10 mg/ml RNaseA)
[51] for 30 min at 48uC, followed by a 15-min incubation at
37.8uC to digest the RNA. The cells (1610
7cells) were suspended
in 100 mlHanks’ balanced salt solution (HBSS) and incubated on
ice for 30 min with fluorescein isothiocyanate (FITC)-conjugated
Annexin V (BD Biosciences) to detect apoptotic cells. The cells
were washed, resuspended in HBSS containing 1 mg/ml PI, and
analyzed by FACS Caliber (BD Biosciences). The effects of cell
death were assessed by Annexin V-FITC flow cytometry as
previously described [52]. Briefly, the spheres of U251-MG cells
were harvested and stained with Annexin V-FITC according to
the instructions of the manufacturer. Cell samples were analyzed
on a FACS and apoptotic fractions were determined.
RNA interference experiment
MSI1 expression was reduced using a pLKO lentiviral vector
(Sigma) expressing targeting and non-targeting sequences. Con-
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shRNA as a negative control was prepared was prepared in 80 ml
of PBS. , 20 ml of virus solution was mixed with culture medium to
transduce U251MG, Daoy, GM1605, and GM1600 cells. Infected
cells were selected by incubation with 2.5 mg/mL puromycin
(Sigma-Aldrich) for 10 days. The cells were then harvested and
lysed. The efficacy and specificity of the shRNAs were evaluated
by immunoblot analysis (Fig. 1).
Virus production
HEK293FT cells (Invitrogen) were transfected with the
lentivirus constructs pCMV-VSV-G-RSV-Rev and pCAG-HIVgp
by using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions [53]. After incubation for 72 hours,
the virus-containing supernatant was collected and centrifuged at
25000 rpm for 90 min at 4uC. Pelleted virus particles were
dissolved in 80 ml of PBS.
RNAi target sequence
MSI1-targeting RNAi
59-CCGGCAAGATGGTGACTCGAACGAACTCGAGTTC-
GTTCGAGTCACCATCTTGTTTTTG-39 in the 39-UTR of
MSI1 mRNA 370 (shown as MSI1-KD(i)) and 59-CCGGCACG-
TTTGAGAGTGAGGACATCTCGAGATGTCCTCACTCT-
CAAACGTGTTTTTG-39 in the 39-UTR (untranslated region)
of MSI1 mRNA 529 (shown as MSI1-KD(ii)) (Oligo ID #
V2HS_280120; Open Biosystems, Huntsville, AL).
Non-targeting control vector 59-CAACAAGATGAAGAG-
CACCAA-39 (MISSION Non-Target shRNA Control Vector
code# SHC002 Sigma)
Immunohistochemistry
Animals were anesthetized and transcardially perfused with 4%
PFA. The whole brain was removed and postfixed for 8 hr in 4%
PFA, soaked overnight in 15% followed by 30% sucrose, and
embedded in OCT compound. Coronal sections 14-mm thick were
made with a Cryostat (Leica, Wetzlar, Germany) and processed
for immunohistochemical analysis.
The tissues were fixed with 4% paraformaldehyde (PFA) in
phosphate-buffered saline (PBS) (pH 7.4), followed by cryopro-
tection with 20% sucrose. Frozen 14-mm-thick tissue sections
were prepared using a cryostat (CM3000, Leica). The slides were
washed 3 times in PBS, blocked for 1 hour in a buffer containing
10% goat serum in PBS, and incubated overnight at 4uCw i t hr a t
anti-MSI1 antibody 14H1 [49]. The slides were washed 3 times
with PBS, and the antigen was visualized with ABC Vectastain
and DAB as substrates (Vector Labs, Burlingame, CA). The
slides were counterstained with Harris-modified hematoxylin
(Thermo-Fisher, Pittsburgh, PA) and mounted in Permount. The
sections were incubated with primary antibodies in TNB
blocking buffer (PerkinElmer) at 4uC overnight, and then with
fluorescent dye-conjugated secondary antibodies at room tem-
perature for 1 hr. The images were observed by fluorescence
microscopy (Axioplan2 Imaging, Carl Zeiss and BZ9000, Key-
ence Osaka, Japan).
Antibodies used in immunocytochemistry
For immunocytochemistry, rat anti-Cyclin B1 (1:500) (Santa
Cruz Biotechnology) was used in addition to antibodies used in
immunoblot analysis shown above. The secondary antibodies were
as follows: Alexa488 conjugated goat anti-mouse IgG (Invitrogen)
(1:1000), Alexa488-conjugated goat anti-rabbit IgG (Invitrogen)
(1:1000), Alexa488-conjugated goat anti-rat IgG (Invitrogen)
(1:1000), Alexa488-conjugated donkey anti-rabbit IgG (Invitrogen)
(1:1000), Alexa488-conjugated donkey anti-rat IgG (Invitrogen)
(1:1000), Alexa555-conjugated goat anti-rat IgG (Invitrogen)
(1:1000), Alexa555-conjugated goat anti-rabbit IgG (Invitrogen)
(1:1000), Alexa555-conjugated donkey anti-goat IgG (Invitrogen)
(1:1000), anti-Hoechst(Sigma-Aldrich) (1:1000), and Alexa568-
conjugated donkey anti-sheep IgG (Molecular Probes) (1:1000).
Xenograft transplantation into mouse brain
All the animal experiments were conducted according to the
Guidelines for the Care and Use of Laboratory Animals of the
Keio University School of Medicine. Mice were anesthetized and
the implantation of partially dissociated human glioma spheres
(1610
4 cells in 3 ml of PBS) into the right striatum was performed
stereotactically (2 mm lateral and 1 mm anterior to bregma; depth
3 mm from dura). We used immunodeficient mice (NOD/SCID
mice; Charles River, Tokyo, Japan) to avoid rejection of the
xenografts. The survival after glioblastoma cell transplantation was
evaluated for up to 2 months.
SA-b-gal staining
Senescence-associated b-galactosidase (SA-b-gal) staining was
performed as described previously [26]. Briefly, the control and
MSI1-KD spheres were washed in PBS, dissociated, fixed with 2%
formamide-0.2% glutaraldehyde in PBS for 5 min at room
temperature, and incubated overnight at 37uC in fresh X-Gal
solution (1 mg/ml X-Gal, 5 mM potassium ferrocyanide, 5 mM
potassium ferricyanide, 150 mM NaCl, and 2 mM MgCl2 in
40 mM citric acid/sodium phosphate buffer, pH 6.0). The next
day, the cells were rinsed with PBS, and the percentages of SA-b-
gal-positive (blue) cells were determined after scoring 100 cells for
each sample using a bright-field microscope.
Statistical analysis
Statistical analyses were performed using Student’s t-test and
Dunnett’s test. Student’s t-test was used to compare the control
shRNA groups with the MSI1-KD groups in the colony-formation
assay, immunocytochemistry, and the cell number assay. Values
are presented as the mean 6 SEM. Significance was accepted at
P,0.05
TUNEL staining
The cells were stained with Hoechst 33258 and then treated
with the ApopTag
Red In Situ Apoptosis Detection Kit (Intergen Co. Ltd, NY,
USA). The number of positive cells was counted by an IN Cell
Analyzer 2000 (GE Healthcare Bioscience).
Bioluminescence Imaging (BLI)
To monitor the tumor growth in live animals, we used the IVIS
systemH (Caliper Life Sciences, Hopkinton, MA). The cells used
for grafting were transduced with a lentivirus containing the click
beetle red Luciferase (CBRluc) coding sequence and a Venus
bicistronic reporter gene connected by an internal ribosomal entry
site (IRES) (EF1a-CBRluc-IRES-Venus). Specifically, the lentivi-
rus was produced with pCSII-EFp-CBR Luc-IRES2-Venus [13].
A Xenogen-IVIS 100-cooled CCD optical macroscopic imaging
system was used for the bioluminescence imaging (BLI). All the
images were analyzed with the Igor (WaveMetrics, Lake Oswego,
OR) and Living Image software (Caliper Life Sciences), and the
optical signal intensity was expressed as photon counts, in units of
photons per second. The results were displayed as a pseudocolor
photon count image superimposed on a gray-scale anatomic
Musashi1-Mediated Modulation of Glioma Growth
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specific region of interest (ROI) that covered the area at and
around the implanted cells. We used the same ROI for all the
animals at all time points to ensure uniform data collection.
Time-lapse imaging assay
Cells were transfected with fucci2;mAG-hGem(1/110), which
labels nuclei in the S/G2/M phases [25]. The virus-infected
(colored) cells were sorted by flow cytometry. Cells stably
expressing the S/G2/M marker were grown in 96-well dishes
in serum-free DMEM HAM/F12 (Sigma-Aldrich) supplemented
with 16B27 (Invitrogen), 20 ng/mL epidermal growth factor
(EGF; Peprotech Invitrogen), and 20 ng/mL fibroblast growth
factor-2 (FGF-2; Peprotech Invitrogen), at 37uC with 5% CO2.
The cells were imaged for 96 hours in an incubator (Tokai Hit)
on the microscope stage. Fifty-one images in the z-axis, both
bright-field and single-color (green), were captured at 20-min
intervals. An inverted microscope (IX-71, Olympus) was fitted
with a Nipkow disc scanning confocal unit (CSU10, Yokogawa
Electric Corp.), EM-CCD camera (iXON BV-887, Andor), filter
wheel, and z motor (Mac5000, Ludl Electronic Products). As our
imaging device has an attached auto xy stage (Sigma Koki),
several spheres can be monitored in one assay. Device control
and image analysis were performed using MetaMorph software
(Universal Imaging).
Self renewing sphere formation was observed by time-lapse
imaging microscopy.
Supporting Information
Figure S1 The spheres were dissociated, and the
dissociated cells were fixed to coverslips and stained
for PH3 in GM1605 cells.
(TIF)
Figure S2 Colonies were dissociated, and the cells were
fixed to coverslips and stained for for cleaved Caspase-3
in GM1605 cells.
(TIF)
Figure S3 Low passage cells from glioblastoma patients
(cell density of 2610
3 cells/well) were assessed for cell
proliferation by cell counting. The total cell count in the
MSI1-KD-treated groups on day 15 was reduced by 39% in the
GM1605 cells, as compared to the control groups.
(TIF)
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